AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33593867
Drug: IV immunoglobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV immunoglobulin (IVIG) treatment
Trial: 33593994
Drug: Non-vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin K antagonist oral anticoagulants (NOAC)
Trial: 33594075
Drug: Neoadjuvant anti-OX40
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant anti-OX40 (MEDI6469) therapy
Trial: 33594602
Drug: CRLX301 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRLX301 at 75 mg/m2 Q3W
Trial: 33596161
Drug: High-risk obstructive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk obstructive sleep apnea treatment
Trial: 33596309
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma GLP-1 concentrations in the obesity clinic group (median 3.3 pmol/L; interquartile range, 2.3-4.3 pmol/L)
Trial: 33597152
Drug: Oral glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoid therapy, immunotherapies, and biologic therapy
Trial: 33598475
Drug: Saffron extract
RxNorm normalized name: saffron extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron extract (30 mg standardized saffron extract for 8 weeks)
Trial: 33598844
Drug: Roux-en-Y gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roux-en-Y gastric bypass (group A: one oral hypoglycemic agent)
Trial: 33598942
Drug: Bendamustine (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (30, 40, or 60 mg/m²) in combination with clofarabine, etoposide, and dexamethasone for 5 days
Trial: 33598942
Drug: Bendamustine (substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (substituted for cyclophosphamide) in combination with clofarabine and etoposide
Trial: 33599941
Drug: High-protein plant-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein plant-based diet (~ 1.6 g kg)
Trial: 33600102
Drug: Intestinal mucosal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intestinal mucosal samples for IgE antibody determination
Trial: 33601057
Drug: AAV8-RS1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV8-RS1 gene therapy
Trial: 33602286
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection of umbilical cord-derived Wharton's Jelly (UC-derived WJ)
Trial: 33602316
Drug: Belinostat (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belinostat (1000 mg/m2) combined with CHOP (Bel-CHOP)
Trial: 33602316
Drug: Belinostat (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belinostat (1000 mg/m2) on Day 1-3 schedule
Trial: 33602316
Drug: Belinostat (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belinostat (1000 mg/m2) on Day 1-5 schedule
Trial: 33602696
Drug: Hexatherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexatherapy regimen composed of adenovirus-based vaccine, IL-15 superagonist (N-803), anti-OX40, anti-4-1BB, anti-PD-L1, and docetaxel.
Trial: 33602926
Drug: Standard TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TB therapy
Trial: 33602926
Drug: Experimental TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental TB treatment (did not reduce Mtb bacterial load)
Trial: 33604400
Drug: Convalescent COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent COVID-19 plasma (CCP) treatment
Trial: 33604458
Drug: Concurrent paclitaxel-based
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent paclitaxel-based chemoradiotherapy (CRT)
Trial: 33604947
Drug: Morphine equivalent
RxNorm normalized name: paregoric 2 MG (as morphine equivalent) in 5 mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine equivalent dose
Trial: 33605445
Drug: Obinutuzumab (GA101;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab (GA101; G) alone (G-mono)
Trial: 33605445
Drug: Obinutuzumab (G)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (G) with fludarabine and cyclophosphamide (G-FC)
Trial: 33605445
Drug: Obinutuzumab (G)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (G) with bendamustine (G-bendamustine)
Trial: 33605465
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (AHT) including β-blockers and/or ACE inhibitors
Trial: 33605465
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with VIT treatment failure
Trial: 34826124
Drug: CZP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 400 mg Q2W
Trial: 33606269
Drug: CZP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 400 mg Q2W and CZP 200 mg Q2W
Trial: 33606269
Drug: CZP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 400 mg Q2W, CZP 200 mg Q2W, and placebo
Trial: 33606312
Drug: Nasal allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal allergen challenge (NAC) with cockroach extract (0.00381-11.9 µg/mL Bla g 1)
Trial: 33606418
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (LTVV), defined as VT of 8 ml kg-1 or less predicted bodyweight (PBW)
Trial: 33606655
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management app delivered via care packages
Trial: 33607477
Drug: NBTXR3 (intratumoural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBTXR3 (intratumoural injection) followed by intensity-modulated radiation therapy (IMRT; 70 Gy)
Trial: 33619368
Drug: Anti-BCMA CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-BCMA CAR T cell therapy
Trial: 33608053
Drug: Lymphodepleting chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting chemotherapy (LDC)
Trial: 33608060
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment with measurement based care (MBC)
Trial: 33608263
Drug: Renin-Angiotensin-Aldosterone System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment
Trial: 33608377
Drug: ABBV-428 administered
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-428 administered intravenously every 2 weeks at doses between 0.01 and 3.6 mg/kg.
Trial: 33609856
Drug: 200 ug
RxNorm normalized name: DROXIDOPA 200 ug ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ug adjunctive estradiol treatment
Trial: 33610169
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with Habit Reversal Training (HRT) and Exposure Response Prevention (ERP)
Trial: 33610169
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with HRT and ERP (individual or group setting)
Trial: 33610169
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with HRT and ERP
Trial: 33610319
Drug: Weekly IV
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly IV paclitaxel with carboplatin and bevacizumab (regimen 2)
Trial: 33610453
Drug: Osimertinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib plus single-agent chemotherapy (n=29)
Trial: 33610453
Drug: Osimertinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib plus chemotherapy
Trial: 33610500
Drug: Haploidentical K562-mb15-41BBL-activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haploidentical K562-mb15-41BBL-activated and expanded NK (NKAE) cells; 13 infusions administered after a lymphodepleting regimen
Trial: 33612455
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg, every 3 weeks)
Trial: 33613701
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor monotherapy
Trial: 33613701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of baseline lesion number (BLN) and tumor mutation burden (TMB)
Trial: 33614477
Drug: Antiviral prophylaxis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiviral prophylaxis
Trial: 33614477
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral prophylaxis (Control)
Trial: 33614504
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bortezomib, cyclophosphamide, and dexamethasone with daratumumab
Trial: 33614504
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bortezomib, cyclophosphamide, and dexamethasone without daratumumab
Trial: 33614888
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg daily for 24 weeks
Trial: 33615207
Drug: NASH patients
RxNorm normalized name: nashipati extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NASH patients with pronounced insulin resistance (IR)
Trial: 33615399
Drug: Macimorelin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macimorelin 0.5 mg/kg
Trial: 33615399
Drug: Macimorelin 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macimorelin 0.75 mg/kg
Trial: 33616416
Drug: Intraperitoneal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal bevacizumab 2.5 mg/kg
Trial: 33616416
Drug: Intraperitoneal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal bevacizumab 5 mg/kg
Trial: 33616416
Drug: Intraperitoneal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal bevacizumab 7.5 mg/kg
Trial: 33616416
Drug: Intraperitoneal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal bevacizumab (all doses)
Trial: 33616758
Drug: Pulse oximetry-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse oximetry-derived peripheral perfusion index (PPI) after 200 mL crystalloid challenge
Trial: 33616758
Drug: Fluid challenge
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid challenge test using 200 mL crystalloid solution
Trial: 33616758
Drug: Additional 300
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional 300 mL crystalloid infusion
Trial: 33617672
Drug: DCLL9718S, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1)
Trial: 33618437
Drug: Low-dose fludarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fludarabine and cyclophosphamide combined with rituximab (FCR); fludarabine reduced to 12 mg/m²
Trial: 33618920
Drug: Hyperuricemic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperuricemic group (SUA ≥7 mg/dL in men and ≥6 mg/dL in women)
Trial: 33619369
Drug: Daratumumab, carfilzomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab, carfilzomib, lenalidomide, and dexamethasone combination
Trial: 33620177
Drug: Cyclic treatment
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic treatment interruption (CTI) of rosuvastatin for 72 weeks (3 treatment-interruption cycles)
Trial: 33620904
Drug: Single purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single purified exosome product (PEP) injection (acute-single)
Trial: 33620904
Drug: Weekly PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly PEP injections (acute-weekly, 4 total injections)
Trial: 33620904
Drug: Delayed single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed single injection (subacute-single)
Trial: 33620918
Drug: MemoryGel Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MemoryGel Breast Implants (primary augmentation)
Trial: 33620918
Drug: MemoryGel Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MemoryGel Breast Implants (revision augmentation)
Trial: 33620918
Drug: MemoryGel Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MemoryGel Breast Implants (primary reconstruction)
Trial: 33620918
Drug: MemoryGel Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MemoryGel Breast Implants (revision reconstruction)
Trial: 33621600
Drug: Inhaled amikacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled amikacin-containing multidrug regimens (including IV amikacin, imipenem or cefoxitin, oral azithromycin, and oral clofazimine if applicable)
Trial: 33621600
Drug: Inhaled amikacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled amikacin-containing multidrug regimens
Trial: 33621914
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control group (DTCG), n = 22
Trial: 33622371
Drug: High TIL
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High TIL treatments (metabolic suppression, hypothermia (< 35 °C), intensive hyperventilation)
Trial: 33622371
Drug: High TIL
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High TIL treatments
Trial: 33622371
Drug: High TIL
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High TIL treatments after day 1
Trial: 33622393
Drug: Preoperative use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative use of pain medications
Trial: 33622508
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment program (3 to 5 in-person sessions + weekly phone calls supported by a mobile app)
Trial: 33622508
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment program
Trial: 33624028
Drug: Elevated neutrophil
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated neutrophil count >7.8 × 10^9/L
Trial: 33624233
Drug: LY3022855 (anti-CSF-1R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 (anti-CSF-1R monoclonal antibody) 2.5 mg/kg QW, 0.3 mg/kg QW, 0.6 mg/kg QW, 1.25 mg/kg Q2W, 1.25 mg/kg QW, 100 mg QW, 150 mg QW
Trial: 33625039
Drug: Cell and
RxNorm normalized name: Antineoplastic cell and gene therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell and gene therapy for HIV disease, specific details on dosage and duration not available.
Trial: 33625039
Drug: Vectored passive
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vectored passive immunity, B cell engineering, T cell engineering, specific details on dosage and duration not available.
Trial: 33625060
Drug: Cafedrine hydrochloride
RxNorm normalized name: cafedrine
DrugBank: Cafedrine (DB12926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafedrine hydrochloride (200 mg) and theodrenaline hydrochloride (10 mg) in 2 ml (C/T)
Trial: 33625371
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) administered intravenously at a loading dose of 30 mg/kg over 15 minutes, followed by a continuous infusion of 1 mg/kg/hour over the next 12 hours.
Trial: 33625371
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline) administered intravenously in an identical manner to VPA.
Trial: 33625721
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day for 16 weeks
Trial: 33625888
Drug: International camps
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: International camps for education and psychosocial support, details on dosage and duration not available.
Trial: 33626238
Drug: Gefitinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib + Chemotherapy
Trial: 33626251
Drug: Risdiplam (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risdiplam (0.08 mg/kg/day) in low-dose cohort
Trial: 33626251
Drug: Risdiplam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risdiplam (0.2 mg/kg/day) in high-dose cohort
Trial: 33626457
Drug: Fever-range whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fever-range whole body hyperthermia (FRWBH) scheduled weekly during re-irradiation; 5 patients received all cycles of FRWBH.
Trial: 33626457
Drug: Re-irradiation using
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-irradiation using volumetric arc hyperfractionated radiotherapy with bi-daily 1.2 Gray (Gy) single fractions and a total dose of 66 Gy to all macroscopic tumor lesions; concomitant chemotherapy mostly with cisplatin (7 patients).
Trial: 33627105
Drug: Antifibrotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrotic therapy
Trial: 33627164
Drug: Moxetumomab pasudotox
RxNorm normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moxetumomab pasudotox (40 µg/kg intravenously on Days 1, 3, and 5 of each 28-day cycle for up to six cycles)
Trial: 33627169
Drug: Helmet CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helmet CPAP treatment
Trial: 33627192
Drug: Amoxicillin treatment
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin treatment in a randomized controlled trial
Trial: 33627313
Drug: D-dimers >1850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimers >1850 ng/mL
Trial: 33627355
Drug: Single high-sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-sensitivity cardiac troponin T (hs-cTnT) measurement <5 ng/L
Trial: 33628355
Drug: Concurrent validity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent validity (preprocedure measurements)
Trial: 33628355
Drug: Concurrent validity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent validity (postprocedure measurements)
Trial: 33628834
Drug: Hybrid Closed
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid Closed Loop (HCL) insulin delivery system with integrated continuous glucose monitoring (CGM)
Trial: 33629188
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS) with warming and cooling sensations (hot tropical ginger, hot mango, cool red fruits, cool lemon, neutral)
Trial: 33629819
Drug: Ticagrelor (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months)
Trial: 33630272
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Tocilizumab (TCZ) therapy
Trial: 33630272
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) therapy with known reasons for discontinuation
Trial: 33630275
Drug: Daratumumab 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab 16 mg/kg monotherapy
Trial: 33630808
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion (100-mL intravenous lipid emulsion)
Trial: 33631349
Drug: Accelerated neuromodulation
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated neuromodulation therapy